Torsemide
- Atc Codes:C03CA04
- CAS Codes:56211-40-6
- PHARMGKB ID:56211-40-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Torasemid; Belgium: Torasemide, Torrem; Bulgaria: Torem, Trifas; Estonia: Torasemid, Torasemide, Trifas; Germany: Setora, Tokid, Toracard, Toradiur, Toragamma, Toral, Torasemid, Torasid, Torasuro, Tordrei, Torein, Torem, Torzus, Torzwas, Unat; Italy: Diuremid, Diuresix, Toradiur, Torasemide; Luxembourg: Torrem; Poland: Diured, Diuver, Toramide, Trifas; Romania: Trifas; Slovenia: Diuver; Spain: Dilutol, Isodiur, Sutril, Torasemida; Sweden: Tohexal, Torahexal, Torarese, Torasemid, Torem; UK: Torem.
North America
USA: Demadex, Torsemide.
Latin America
Argentina: Torem.
Asia
Japan: Luprac.
Drug combinations
Chemistry
Torsemide: C~16~H~20~N~4~O~3~S. Mw: 348.42. (1) 3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-; (2) 1-Isopropyl-3-[(4-m-toluidino-3-pyridyl)sulfonyl]urea. CAS-56211-40-6 (1989).
Pharmacologic Category
Loop Diuretics. (ATC-Code: C03CA04).
Mechanism of action
Inhibits reabsorption of sodium and chloride in ascending loop of Henle and distal renal tubule, interfering with chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium.
Therapeutic use
Management of edema associated with congestive heart failure and hepatic or renal disease. Used alone or in combination with antihypertensives in treatment of hypertension. I.V. form indicated when rapid onset is desired.
Pregnancy and lactiation implications
A decrease in fetal weight, increase in fetal resorption, and delayed fetal ossification occurred in animal studies. Excretion in breast milk unknown (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to torsemide, any component of the formulation, or any sulfonylureas. Anuria.
Warnings and precautions
Use in sulfonylurea allergy specifically contraindicated in product labeling, however, risk of cross-reaction exists in allergy to any of these compounds (avoid use when previous reaction severe). Nephrotoxicity might occur (oliguria, azotemia, and reversible increases in BUN and creatinine); fluid status and renal function should be monitored. Excess amounts can lead to profound diuresis with fluid and electrolyte loss (loop diuretics are potent diuretics). In cirrhosis, avoid electrolyte and acid/base imbalances which might lead to hepatic encephalopathy. Rapid I.V. administration, renal impairment, excessive doses, and concurrent use of other ototoxins associated with ototoxicity (seen with oral torsemide). Co-administration of antihypertensives may increase risk of hypotension.